| 3.81 -0.11 (-2.81%) | 09-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.99  |
1-year : | 7.45 |
| Resists | First : | 5.12 |
Second : | 6.38 |
| Pivot price | 3.88 |
|||
| Supports | First : | 3.1 | Second : | 2.58 |
| MAs | MA(5) : | 3.84 |
MA(20) : | 4.2 |
| MA(100) : | 7.33 |
MA(250) : | 9.29 | |
| MACD | MACD : | -0.6  |
Signal : | -0.7 |
| %K %D | K(14,3) : | 47 |
D(3) : | 39 |
| RSI | RSI(14): 37.3 |
|||
| 52-week | High : | 36 | Low : | 2.15 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ XCUR ] has closed above bottom band by 42.5%. Bollinger Bands are 65.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.05 - 4.07 | 4.07 - 4.1 |
| Low: | 3.75 - 3.77 | 3.77 - 3.8 |
| Close: | 3.76 - 3.81 | 3.81 - 3.85 |
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Mon, 04 Aug 2025
Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements - Business Wire
Fri, 27 Jun 2025
Exicure Reports Surprise Q1 Profit, But Warns Cash Running Out for Operations - Stock Titan
Mon, 14 Apr 2025
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study o - GuruFocus
Mon, 14 Apr 2025
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma - Business Wire
Fri, 11 Apr 2025
Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML) - Business Wire
Thu, 23 Jan 2025
Exicure Stock Soars Over 25% On Acquisition Of GPCR Therapeutics’ U.S. Unit: Retail Chatter Spikes - Stocktwits
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 6 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 63.1 (%) |
| Held by Institutions | 12.8 (%) |
| Shares Short | 30 (K) |
| Shares Short P.Month | 55 (K) |
| EPS | -3.86 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.39 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -35.5 % |
| Return on Equity (ttm) | -150.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.28 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.31 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.99 |
| PEG Ratio | 0 |
| Price to Book value | 2.72 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|